A pivotal trial of epacadostat in combination with pembrolizumab in patients with first-line bladder cancer
Phase of Trial: Phase III
Latest Information Update: 31 Mar 2017
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer
- Focus Registrational; Therapeutic Use
- 31 Mar 2017 This trial will be conducted under the expanded collaboration for seven pivotal trials of Epacadostat and KEYTRUDA (pembrolizumab) between an Incyte Corporation and Merck, as reported in an Incyte Corporation media release.
- 12 Jan 2017 New trial record
- 09 Jan 2017 According to an Incyte Corporation media release, this trial is expected to initiate in 2017.